antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2021-66-11-12-44-51antibiotics-878Research ArticleОБЗОРЫREVIEWSСтратегии применения антибиотиков при инфекции мочевыводящих путей у детейStrategies of antibiotic treatment of urinary tract infections in childrenhttps://orcid.org/0000-0003-0936-5551БунятянН. Д.BunyatyanN. D.

  Бунятян Наталья Дмитиевна — д. ф. н., профессор,главный аналитик центра клинической фармакологии, заведующая кафедрой кафедрой фармацевтической технологии и фармакологии федерального государственного автономного образовательного учреждения высшего образования

 ResearcherID: D-3071-2018. eLIBRARY SPIN-код: 9853-1232.Scopus Author ID: 6506018057 

Петровский бульвар, 8, стр. 2., г. Москва, 127051 

 Natalya D. Bunyatyan — D. Sc. in pharmaceutical sciences,Professor

ResearcherID: D-3071-2018.eLIBRARY SPIN: 9853-1232. Scopus Author ID: 6506018057 

8/2 Petrovsky blvd., Moscow, 127051

Bunyatyan@expmed.ruhttps://orcid.org/0000-0002-0258-4092ПетровВ. И.PetrovV. I.

 Петров Владимир Иванович — д. м. н., профессор, академик РАН, заведующий кафедрой клинической фармакологии и интенсивной терапии, директор

Волгоград

ResearcherID: D-9412-2016. eLIBRARY SPIN-код: 148296.

Scopus Author ID: 7402843021 

 Vladimir I. Petrov — D. Sc. in medicine, Professor

Volgograd

ResearcherID: D-9412-2016.eLIBRARY SPIN: 148296. Scopus Author ID: 7402843021 

https://orcid.org/0000-0002-7311-4549ШаталоваО. В.ShatalovaO. V.

 Шаталова Ольга Викторовна — д. м. н., профессор кафедры клинической фармакологии и интенсивной терапии

Волгоград

eLIBRARY SPIN-код: 478471. Scopus Author ID: 57188798913 

 Olga V. Shatalova — D. Sc. in medicine

Volgograd

eLIBRARY SPIN: 478471. Scopus Author ID: 57188798913 

https://orcid.org/0000-0002-8237-8335ПономареваА. ВPonomarevaA. V.

 Пономарева Анжелика Викторовна — д. м. н., профессоркафедры клинической фармакологии и интенсивной терапии, заведующая лабораторией клинической фармакологии

Волгоград

ResearcherID: H-4714-2013. eLIBRARY SPIN-код: 614388  

 Angelika V. Ponomareva — D. Sc. in medicine

Volgograd

ResearcherID: H-4714-2013. eLIBRARY SPIN code:614388 

https://orcid.org/0000-0002-7322-3323ГородецкаяГ. И.GorodetskayaG. I.

 Городецкая Галина Ивановна — старший аналитик центраклинической фармакологии

Москва

 ResearcherID: D-3596-2018. eLIBRARY SPIN-код: 8346-3293. Scopus Author ID: 57196437441 

 Galina I. Gorodetskaya — Senior Analyst of the Center forClinical Pharmacology

Moscow

ResearcherID: D-3596-2018. eLIBRARYSPIN: 8346-3293. Scopus Author ID: 57196437441 

https://orcid.org/0000-0001-7024-5546ПрокофьевА. Б.ProkofievА. В.

 Прокофьев Алексей Борисович — д. м. н., профессор, директор центра клинической фармакологии, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней

Москва

ResearcherID: D-2961-2018. eLIBRARY SPIN-код: 1003-0672. Scopus Author ID: 57189082881 

 Alexey B. Prokofiev — D. Sc. in medicine, Professor

Moscow

ResearcherID: D-2961-2018. eLIBRARY SPIN: 1003-0672.Scopus Author ID: 57189082881 

ФГБУ «Научный центр экспертизы средств медицинского применения» МЗ РФ; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова МЗ РФРоссияScientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» МЗ РФ; Научный центр инновационных лекарственных средств с опытно-промышленным производствомРоссияVolgograd State Medical University of the Ministry of Health of the Russian Federation; Scientific Center for Innovative Medicines with Pilot ProductionRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова МЗ РФРоссияI. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation;Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова МЗ РФ;РоссияI. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation; Volgograd Scientific Medical CenterRussian FederationФГБУ «Научный центр экспертизы средств медицинского применения» МЗ РФ; ФГБОУ ВО «Волгоградский государственный медицинский университет» МЗ РФРоссияScientific Centre for Expert Evaluation of Medicinal Products of the Ministry of Health of the Russian Federation; Volgograd State Medical University of the Ministry of Health of the Russian FederationRussian Federation2021150320226611-124451Copyright © Бунятян Н.Д., Петров В.И., Шаталова О.В., Пономарева А.В., Городецкая Г.И., Прокофьев А.Б., 20222022Бунятян Н.Д., Петров В.И., Шаталова О.В., Пономарева А.В., Городецкая Г.И., Прокофьев А.Б.Bunyatyan N.D., Petrov V.I., Shatalova O.V., Ponomareva A.V., Gorodetskaya G.I., Prokofiev А.В.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/878

В обзоре представлены основные направления антибиотикотерапии, связанные с рациональной фармакотерапией инфекции мочевыводящих путей (ИМВП) в педиатрической практике. Являясь значимой проблемой в детском возрасте, ИМВП часто приводит к рецидивированию и формированию более тяжёлых форм заболеваний мочевыводящей системы. Своевременная и адекватная по этиологическому фактору, выбору препарата, соответствию дозы, пути введения и возрасту пациента антибактериальная терапия позволяет избежать дальнейшего прогрессирования заболевания и инвалидизации пациентов.

The review presents the main directions of antibiotic therapy associated with rational pharmacotherapy of urinary tract infections (UTIs) in pediatric practice. As a serious pediatric problem, UTIs are often prone to recurrence, as well as may lead to the formation of more severe forms of urinary system diseases. Antibiotic therapy, timely and adequate in terms of etiological factors, drug and dosage choice, route of administration, as well as patient’s age, allows to avoid further progression of the disease, as well as development of disability in patients.

инфекции мочевыводящих путей у детейантибактериальная терапияurinary tract infections in childrenantibiotic therapyReferencesShaikh N., Morone N.E., Bost J.E., Farrell M.H. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008; 27 (4): 302–308. doi: 10.1097/INF.0b013e31815e4122.Shaikh N., Morone N.E., Bost J.E., Farrell M.H. Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J. 2008; 27 (4): 302–308. doi: 10.1097/INF.0b013e31815e4122.O'Brien K., Stanton N., Edwards A., Hood K., Butler C.C. Prevalence of urinary tract infection (UTI) in sequential acutely unwell children presenting in primary care: exploratory study. Scand J Prim Health Care. 2011; 29 (1): 19–22. doi: 10.3109/02813432.2011.554268.O'Brien K., Stanton N., Edwards A., Hood K., Butler C.C. Prevalence of urinary tract infection (UTI) in sequential acutely unwell children presenting in primary care: exploratory study. Scand J Prim Health Care. 2011; 29 (1): 19–22. doi: 10.3109/02813432.2011.554268.Chang S.L., Shortliffe L.D. Pediatric urinary tract infections. Pediatr Clin North Am. 2006; 53: 379–400. doi:10.1016/j.pcl.2006.02.011.Chang S.L., Shortliffe L.D. Pediatric urinary tract infections. Pediatr Clin North Am. 2006; 53: 379–400. doi:10.1016/j.pcl.2006.02.011.Leroy S., Gervaix A. Procalcitonin, a useful biomarker in pediatric urinary tract infection. Arch Pediatr. 2013; 20 (1): 54–62. doi:10.1016/j.arcped.2012.10.025.Leroy S., Gervaix A. Procalcitonin, a useful biomarker in pediatric urinary tract infection. Arch Pediatr. 2013; 20 (1): 54–62. doi:10.1016/j.arcped.2012.10.025.Федеральные клинические рекомендации «Инфекция мочевыводящих путей у детей». М.: Союз педиатров России, 2018.Federal'nye klinicheskie rekomendacii «Infekciya mochevyvodyashchih putej u detej». Moscow: Soyuz pediatrov Rossii, 2018. (in Russian)]Shaikh N., Craig J.C., Rovers M.M. et al. Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr. 2014; 168 (10): 893–900. doi: 10.1001/jamapediatrics.2014.637.Shaikh N., Craig J.C., Rovers M.M. et al. Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr. 2014; 168 (10): 893–900. doi: 10.1001/jamapediatrics.2014.637.Dahlén G., Blomqvist S., Almståhl A., Carlén A. Virulence factors and antibiotic susceptibility in enterococci isolated from oral mucosal and deep infections. J Oral Microbiol. 2012; 4. doi:10.3402/jom.v4i0.10855.Dahlén G., Blomqvist S., Almståhl A., Carlén A. Virulence factors and antibiotic susceptibility in enterococci isolated from oral mucosal and deep infections. J Oral Microbiol. 2012; 4. doi:10.3402/jom.v4i0.10855.Chang S.L., Shortliffe L.D. Pediatric urinary tract infections. Pediatr Clin North Am. 2006; 53 (3): 379. doi: 10.1016/j.pcl.2006.02.011.Chang S.L., Shortliffe L.D. Pediatric urinary tract infections. Pediatr Clin North Am. 2006; 53 (3): 379. doi: 10.1016/j.pcl.2006.02.011.Montini G., Tullus K., Hewitt I. Febrile urinary tract infections in children. N Engl J Med. 2011; 365 (3): 239–250. doi:10.1056/NEJMra1007755.Montini G., Tullus K., Hewitt I. Febrile urinary tract infections in children. N Engl J Med. 2011; 365 (3): 239–250. doi:10.1056/NEJMra1007755.Shaikh N., Hoberman A. Urinary tract infections in children: epidemiology and risk factors. In: Edwards M.S., Mattoo T.K. eds. UpToDate. 2019.Shaikh N., Hoberman A. Urinary tract infections in children: epidemiology and risk factors. In: Edwards M.S., Mattoo T.K. eds. UpToDate. 2019.Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011; 128 (3): 595–610. doi:10.1542/peds.2011-1330.Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011; 128 (3): 595–610. doi:10.1542/peds.2011-1330.Miller W.R., Munita J.M., Arias C.A. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther. 2014; 12 (10): 1221–1236. doi: 10.1586/14787210.2014.956092.Miller W.R., Munita J.M., Arias C.A. Mechanisms of antibiotic resistance in enterococci. Expert Rev Anti Infect Ther. 2014; 12 (10): 1221–1236. doi: 10.1586/14787210.2014.956092.Nallapareddy S.R., Sillanpää J., Mitchell J. et al. Conservation of Ebptype pilus genes among Enterococci and demonstration of their role in adherence of Enterococcus faecalis to human platelets. Infect Immun. 2011; 79 (7): 2911–2920. doi:10.1128/IAI.00039-11.Nallapareddy S.R., Sillanpää J., Mitchell J. et al. Conservation of Ebptype pilus genes among Enterococci and demonstration of their role in adherence of Enterococcus faecalis to human platelets. Infect Immun. 2011; 79 (7): 2911–2920. doi:10.1128/IAI.00039-11.Kaufman D., Fairchild K.D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004; 17 (3): 638–680. doi: 10.1128/CMR.17.3.638-680.2004.Kaufman D., Fairchild K.D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004; 17 (3): 638–680. doi: 10.1128/CMR.17.3.638-680.2004.European Association of Urology (EAU)-European Society for Paediatric Urology (ESPU): Guidelines on paediatric urology (2019).European Association of Urology (EAU)-European Society for Paediatric Urology (ESPU): Guidelines on paediatric urology (2019).Public Health England (PHE): Diagnosis of urinary tract infections – Quick reference tool for primary care for consultation and local adaptation (2019).Public Health England (PHE): Diagnosis of urinary tract infections – Quick reference tool for primary care for consultation and local adaptation (2019).National Institute for Health and Care Excellence (NICE): Clinical guideline on urinary tract infection in under 16s — Diagnosis and management (2018).National Institute for Health and Care Excellence (NICE): Clinical guideline on urinary tract infection in under 16s — Diagnosis and management (2018).Infectious Diseases Society of America (IDSA): Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. 8.Infectious Diseases Society of America (IDSA): Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. 8.Mathew J. L. Can we predict antibiotic-resistance in urinary tract infection/ J. L. Mathew, R. Sinha. Indian Pediatrics. 2016; 53 (6): 519–521.Mathew J. L. Can we predict antibiotic-resistance in urinary tract infection/ J. L. Mathew, R. Sinha. Indian Pediatrics. 2016; 53 (6): 519–521.Габриелян Н.И., Горская Е.М., Цирульникова О.М. Факторы риска и нозокомиальные инфекции, вызываемые энтерококками. Вестник трансплантологии и искусственных органов. 2015; 17 (2): 64–69.Gabrielyan N. I., Gorskaya E. M., Cirul'nikova O. M. Faktory riska i nozokomial'nye infekcii, vyzyvaemye enterokokkami. Vestnik transplantologii i iskusstvennyh organov. 2015; 17 (2): 64–69. (in Russian)]Yakubov R., van den Akker M., Machamad K., Hochberg A., Nadir E., Klein A. Antimicrobial resistance among uropathogens that cause childhood community-acquired urinary tract infections in central Israel. Pediatr Infect Dis J. 2017; 36 (1): 113–115. doi: 10.1097/INF.0000000000001373.Yakubov R., van den Akker M., Machamad K., Hochberg A., Nadir E., Klein A. Antimicrobial resistance among uropathogens that cause childhood community-acquired urinary tract infections in central Israel. Pediatr Infect Dis J. 2017; 36 (1): 113–115. doi: 10.1097/INF.0000000000001373.Bryce A., Hay A.D., Lane I.F., Thornton H.V., Wootton M., Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016; 352: i939. Published 2016 Mar 15. doi: 10.1136/bmj.i939.Bryce A., Hay A.D., Lane I.F., Thornton H.V., Wootton M., Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016; 352: i939. Published 2016 Mar 15. doi: 10.1136/bmj.i939.Bryce A., Costelloe C., Wootton M., Butler C.C., Hay A.D. Comparison of risk factors for, and prevalence of, antibiotic resistance in contaminating and pathogenic urinary Escherichia coli in children in primary care: prospective cohort study. J Antimicrob Chemother. 2018; 73 (5): 1359–1367. doi: 10.1093/jac/dkx525.Bryce A., Costelloe C., Wootton M., Butler C.C., Hay A.D. Comparison of risk factors for, and prevalence of, antibiotic resistance in contaminating and pathogenic urinary Escherichia coli in children in primary care: prospective cohort study. J Antimicrob Chemother. 2018; 73 (5): 1359–1367. doi: 10.1093/jac/dkx525.Degnan L.A., Milstone A.M., Diener-West M., Lee C.K. Extended-Spectrum Beta-Lactamase Bacteria From Urine Isolates in Children. J Pediatr Pharmacol Ther. 2015; 20 (5): 373–377. doi: 10.5863/1551-6776-20.5.373.Degnan L.A., Milstone A.M., Diener-West M., Lee C.K. Extended-Spectrum Beta-Lactamase Bacteria From Urine Isolates in Children. J Pediatr Pharmacol Ther. 2015; 20 (5): 373–377. doi: 10.5863/1551-6776-20.5.373.The SCOUT study: Short course therapy for urinary tract infections in children (SCOUT). https://clinicaltrials.gov/ct2/show/NCT01595529 (2019).The SCOUT study: Short course therapy for urinary tract infections in children (SCOUT). https://clinicaltrials.gov/ct2/show/NCT01595529 (2019).Hoberman A., Wald E.R., Hickey R.W. et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics. 1999; 104 (1): 79.Hoberman A., Wald E.R., Hickey R.W. et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics. 1999; 104 (1): 79.Degnan L.A., Milstone A.M., Diener-West M., Lee C.K. Extended-Spectrum Beta-Lactamase Bacteria From Urine Isolates in Children. J Pediatr Pharmacol Ther. 2015; 20 (5): 373–377. doi: 10.5863/1551-6776-20.5.373.Degnan L.A., Milstone A.M., Diener-West M., Lee C.K. Extended-Spectrum Beta-Lactamase Bacteria From Urine Isolates in Children. J Pediatr Pharmacol Ther. 2015; 20 (5): 373–377. doi: 10.5863/1551-6776-20.5.373.Montini G., Toffolo A., Zucchetta P. et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ. 2007; 335 (7616): 386. doi: 10.1136/bmj.39244.692442.55.Montini G., Toffolo A., Zucchetta P. et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ. 2007; 335 (7616): 386. doi: 10.1136/bmj.39244.692442.55.

The authors declare that there are no conflicts of interest present.